Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165798 · ClinicalTrials.gov registry record
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- 1,065
- Enrollment target
- 20
- Study locations
NCT04165798 is a study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,065 participants, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (237% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT04165798, a study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- 1,065 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tumor Imaging
- PROCEDURE Tumor Tissue Collection
- PROCEDURE Blood Sample Collection
Study Locations (20)
California
- City of Hope ( Site 0014) - Duarte
- UCSF Medical Center at Mission Bay ( Site 0007) - San Francisco
Massachusetts
- Massachusetts General Hospital ( Site 0003) - Boston
- Dana Farber Cancer Institute ( Site 0002) - Boston
Ohio
- Cleveland Clinic Main ( Site 0006) - Cleveland
- Ohio State University Comprehensive Cancer Center ( Site 0015) - Columbus
Arizona
- Banner MD Anderson Cancer Center ( Site 0001) - Gilbert
District of Columbia
- Georgetown University ( Site 0036) - Washington D.C.
Kentucky
- University of Kentucky Markey Cancer Center ( Site 0019) - Lexington
Maryland
- MedStar Franklin Square Medical Center ( Site 0033) - Baltimore
Nebraska
- Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,065 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2032-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04165798
The ClinicalTrials.gov registry entry for NCT04165798 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,065 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (237% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Tumor Imaging is the first listed.
NCT04165798 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT04165798 about?
NCT04165798 is a clinical study titled "KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)". This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substud...
What is the current status of trial NCT04165798?
This trial is currently recruiting. The enrollment target is 1,065 participants. The study started on 2019-12-19. Estimated completion is 2032-02-13.
What conditions does trial NCT04165798 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04165798?
The interventions under investigation include: Tumor Imaging (DIAGNOSTIC_TEST), Tumor Tissue Collection (PROCEDURE), Blood Sample Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04165798?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04165798 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.